Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sigma Healthcare Ltd (ASX: SIG) shares surged 9% on Thursday and are the most actively traded stock on their first day of trading post-merger with Chemist Warehouse.

The Sigma share price rose by 9.4% to an intraday high of $3.02 per share today.

The stock has since retraced a little to be trading at $2.94, up 6.52%.

The scheme of arrangement between the two companies was officially implemented yesterday, and about 4.3 billion unescrowed new Sigma shares began trading today.

A group of people in a corporate setting do a collective high five.

Image source: Getty Images

First day of trading for repackaged Sigma Healthcare shares

At the time of writing, almost 128.5 million Sigma shares have been traded on Thursday, making it the most traded stock of the day, according to CommSec data.

Some of this trading is likely Chemist Warehouse franchisees offloading their holdings.

This blockbuster merger sure has excited the market, and today's share price leap indicates continued optimism for the future.

The Sigma share price has soared since the proposal was announced on 11 December 2023.

The excitement surrounding the deal prompted many investors to buy Sigma shares.

The new demand resulted in Sigma becoming the No. 1 ASX 200 healthcare share for price growth last year.

Sigma shareholders were thrilled with the proposed deal and voted overwhelmingly in favour of it last month.

Today, Sigma is the ASX 200's second-largest healthcare stock with a market capitalisation of $31.84 billion.

Shares held under escrow

Sigma now officially holds all of the ordinary shares in CW Group Holdings Limited, and Chemist Warehouse is now a wholly owned subsidiary of Sigma Healthcare.

A total of 9.9 billion shares were issued as part of the consideration for Sigma's purchase.

However, approximately 5.6 billion remain under escrow.

Chemist Warehouse shareholders who were entitled to receive consideration got just under 45 cents in cash and just over 6.3 new Sigma shares for each Chemist Warehouse share held.

Sigma estimated the market value of those new shares at $2.83 per share.

The 5.6 billion new Sigma shares under escrow were issued in three separate parcels to Chemist Warehouse co-founders Jack Gance and Sam Gance, and CEO Mario Verrocchi.

Sigma said the trio was "committed to the long-term value creation opportunities available to Sigma" post-merger and had therefore agreed to voluntary escrow arrangements.

Subject to certain exceptions, they cannot sell any of their escrowed shares during the First Escrow Period, defined as between now and the earlier of 31 August or the close of trading on the day that Sigma releases its financial results for the period ending 30 June this year.

They cannot sell 90% of their escrowed shares between the end of the First Escrow Period and the earlier of either 31 August 2026 or the close of trading on the day that Sigma releases its financial results for the period ending 30 June 2026.

Jack Gance and Mario Verrocchi, along with Chemist Warehouse's chief property officer Damien Gance, and chief people officer Danielle Di Pilla, have been appointed to the Sigma board.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why this ASX healthcare stock is at the cusp of a 'Transformational Opportunity' – Expert

This ASX healthcare stock is one to watch.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
ASX Share Market News

Earnings preview: can Cochlear shares rebound?

A decade low share price meets a make-or-break result.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Healthcare Shares

Why I'm watching CSL shares like a hawk in August

A low valuation will look very different depending on what management says about the year ahead.

Read more »